'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Gland Pharma has declined 7.32% to Rs 1424.91 crore. Operating profit margin has jumped from 23.33% to 24.39%, leading to 3.11% decline in operating profit to Rs 347.51 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 37.82% to 38.46%. Purchase of finished goods cost fell from 0.44% to 0.20%. Employee cost increased from 23.14% to 24.44%. Other expenses fell from 14.99% to 14.14%. Power and Oil fuel cost fell from 3.81% to 3.44%.
Other income rose 4.46% to Rs 44.03 crore. PBIDT fell 2.31% to Rs 391.54 crore. Provision for interest fell 25.20% to Rs 7.45 crore. Loan funds declined from Rs 372.17 crore as of 31 March 2024 to Rs 313.73 crore as of 31 March 2025. &n...
Pleaselogin & subscribe to view the full report.
More Reports
|
|